연구동향 분석
박사

Blood pressure-lowering effect of Korean red ginseng associated with decreased circulating Lp-PLA2 activity and lysophosphatidylcholines and increased dihydrobiopterin level in prehypertensive subjects

차태웅 2015년

논문상세정보
인용/피인용
' Blood pressure-lowering effect of Korean red ginseng associated with decreased circulating Lp-PLA2 activity and lysophosphatidylcholines and increased dihydrobiopterin level in prehypertensive subjects' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • blood pressure
  • lp-pla2
  • lysopc
  • metabolites
  • red ginseng
  • 대사체
  • 혈압
  • 홍삼
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
488 0

0.0%

' Blood pressure-lowering effect of Korean red ginseng associated with decreased circulating Lp-PLA2 activity and lysophosphatidylcholines and increased dihydrobiopterin level in prehypertensive subjects' 의 참고문헌

  • Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 inatherosclerosis: biology, epidemiology, and possible therapeutic target. ArteriosclerThromeb Vasc Biol. 2005;25:923-931.
  • Wilensky, R. L., Shi, Y., Mohler, E. R., Hamamdzic, D., Burgert, M. E., Li, J., Macphee,C. H. Inhibition of lipoprotein-associated phospholipase A2 reduces complexcoronary atherosclerotic plaque development. Nature Medicine. 2008;14:1059-1066.
  • Vuksan V, Stavro M, Woo M, Leiter LA, Sung MK, Sievenpiper JL. Korean redginseng (Panax ginseng) can lower blood pressure in individuals with hypertension: arandomized controlled trial. Proceedings of the 9th International Ginseng Symposium;2006, Geumsan, Chungnam, Korea, Korean Society of Ginseng.36
  • Takaku, T., Kameda, K., Matsuura, Y., Sekiya, K. and Okuda, H., Studies on insulinlikeSubstances in Korean Red Ginseng, Planta Medica. 1990;56:27.
  • Takahashi M, Okazaki H, Ogata Y, Takeuchi K, Ikeda U, Shimada K.Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism. Atherosclerosis. 2002Apr;161:387-394.
  • Sung, J., Han, K. H., Zo, J. H., Park, H. J., Kim, D. H., & Oh, B. H. Effects of redginseng upon vascular endothelial function in patients with essential hypertension. TheAmerican Journal of Chinese Medicine. 2000;28:205-216.
  • Sung J, Han KH, Zo JH, et al. Effects of redginseng upon vascular endothelial functionin patients with essential hypertension. Am J Chin Med. 2000;28:205?216.
  • Sudhir K. Lipoprotein-associated phospholipase A2 vascular inflammation andcardiovascular risk prediction. Vasc Health Risk Manag. 2006;2:153-156.
  • Suckling, C. J., Gibson, C. L., Huggan, J. K., Morthala, R. R., Clarke, B., Kununthur,S., Papale, D. 6-Acetyl-7,7-dimethyl-5,6,7,8-tetrahydropterin is an activator of nitricoxide synthases. Bioorganic & Medicinal Chemical Letters. 2008;18:1563-1566.
  • Subbaiah PV, Chen CH, Bagdade JD, Albers JJ. Substrate specificity of plasmalysolecithin acyltransferase and the molecular species of lecithin formed by the reaction.J Biol Chem. 1985; 260: 5308?5314.
  • Su, T. C., Jeng, J. S., Chien, K. L., Sung, F. C., Hsu, H. C., & Lee, Y. T. Hypertensionstatus is the major determinant of carotid atherosclerosis: a community-based study inTaiwan. Stroke. 2001;32:2265-2271.
  • Shils, M. E., Shike, M., Ross, A. C., & Cousins, R. J. (Ed.). Energy needs: assessmentand requirements - Modern Nutrition In Health And Disease. 2006;10:136-148.
  • Safaya R, Chai H, Kougias P, Lin P, Lumsden A, Yao Q, Chen C. Effect oflysophosphatidylcholine on vasomotor functions of porcine coronary arteries. J SurgRes. 2005;126:182-188.37
  • Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Adams, R. J., Berry, J. D., Brown, T. M.,Wylie-Rosett, J. (2011). Heart disease and stroke statistics-2011 update: a report fromthe American Heart Association. Circulation. 2011;123:e18-e209.
  • Rhee, M. Y., Kim, Y. S., Bae, J. H., Nah, D. Y., Kim, Y. K., Lee, M. M., & Kim, H. Y.Effect of Korean red ginseng on arterial stiffness in subjects with hypertension. Journalof Alternative Complementary Medicine. 2011;17:45-49.
  • Rhee, M. Y., Cho, B., Kim, K. I., Kim, J., Kim, M. K., Lee, E. K., & Kim, C. H. Bloodpressure lowering effect of Korea ginseng derived ginseol K-g1. The American Journalof Chinese Medicine. 2014;42:605-618.
  • Reddy, K. J., Singh, M., Bangit, J. R., & Batsell, R. R. The role of lipoproteinassociatedphospholipase A2 on cardiovascular disease risk assessment and plaquerupture: a clinical review. Journal of Clinical Lipidology. 2009;3:85-93.
  • Ramachandran S. Vasan, MD; Alexa Beiser, PhD; Sudha Seshadri, MD; Martin G.Larson, ScD; William B. Kannel, MD; Ralph B. D'Agostino, PhD; Daniel Levy, MD.Residual lifetime risk for developing hypertension in middle-aged women and men.JAMA. 2002;287:1003-1010.
  • Portman OW, Alexander M. Lysophosphatidylcholine concentrations and metabolismin aortic intima plus inner media: effect of nutritionally induced atherosclerosis. J LipidRes. 1969;10:158?165.
  • Philadelphia, PA: Lippincott Williams & Wilkins.Siegel, R. K. Ginseng and high bloodpressure. JAMA. 1980; 243:32.
  • Park, J. B., Kwon, S. K., Nagar, H., Jung, S. B., Jeon, B. H., Kim, C. S., Kim, C. S. Rg3-enriched Korean red ginseng improves vascular function in spontaneously hypertensiverats. Journal of Ginseng Research. 2014;38:244-250.
  • Okuda, H., Zheng, Y., Matsuura, Y., Takaku, T. and Kameda, K., Proceeding of 6th intl.Ginseng Symp., Seoul, Korea. 1993:110
  • Okuda, H., Medical Korean Ginseng 95, Kyoritsu Publishing Company. 1984:233
  • Nam, K. Y. Contemporary Korean Ginseng: Chemical Constituents and BiologicalActivity; Korea Ginseng and Tobacco Research Institute: Daejeon, Korea, 1996;3:56-134.
  • Murugesan G, Fox PL. Role of lysophosphatidylcholine in the inhibition of endothelialcell motility by oxidized low density lipoprotein. J Clin Invest. 1996;97:2736?2744.38
  • Murugesan G, Chisolm GM, Fox PL. Oxidized low density lipoprotein inhibits themigration of aortic endothelial cells in vitro. J Cell Biol. 1993;120:1011?1019.
  • Mucalo, I., Jovanovski, E., Raheli?, D., Bo?ikov, V., Romi? Z, & Vuksan V. (2013).Effect of American ginseng (Panax quinquefolius L.) on arterial stiffness in subjectswith type-2 diabetes and concomitant hypertension. Journal of Ethnopharmacology.2013;150: 148-153.
  • Matsumoto, T., Kobayashi, T., & Kamata, K. Role of lysophosphatidylcholine (LPC)in atherosclerosis. Current Medicinal Chemistry. 2007;14: 3209-3220.
  • MacPhee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, Leake DS, MillinerKJ, Patterson RA, Suckling KE, Tew DG, Hickey DM. Lipoproteinassociatedphospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactiveproducts during the oxidation of low-density lipoprotein: use of a novel inhibitor.Biochem J. 1999;338:479-487.
  • Lp-PLA(2) Studies Collaboration, Thompson A, Gao P, Orfei L, Watson S, DiAngelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, HofmanA, Packard C, Thompson SG, Collins R, Danesh J. Lipoproteinassociatedphospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborativeanalysis of 32 prospective studies. Lancet. 2010;375:1536-1544.
  • Liu SY, Lu X, Choy S, Dembinski TC, Hatch GM, Mymin D, Shen X, Angel A, ChoyPC, Man RY. Alteration of lysophosphatidylcholine content in low density lipoproteinafter oxidative modification: relationship to endothelium dependent relaxation.Cardiovasc Res. 1994;28:1476?1481.
  • Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usualblood pressure to vascular mortality: a meta-analysis of individual data for one millionadults in 61 prospective studies. Lancet. 2002;360:1903?1913.
  • Lavi S, McConnell JP, Rihal CS, Prasad A, Mathew V, Lerman LO, Lerman A. Localproduction of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine inthe coronary circulation: association with early coronary atherosclerosis andendothelial dysfunction in humans. Circulation.2007;115:2715-2721.
  • Kougias P, Chai H, Lin PH, Lumsden AB, Yao Q, Chen C. Lysophosphatidylcholineand secretory phospholipase A2 in vascular disease: mediators of endothelialdysfunction and atherosclerosis. Med Sci Monit. 2006;12:RA5-16.
  • Kim, M., Jung, S., Kim, S. Y., Lee, S. H., & Lee, J. H. Prehypertension-associatedelevation in circulating lysophosphatidlycholines, Lp-PLA2 activity, and oxidativestress. PLoS One. 2014;9:e96735.
  • Kim, H. J., Cho, C. W., Hwang, J. T., Son, N., Choi, J. H., Shim, G. S., & Han, C. K.LC-MS-based metabolomic analysis of serum and livers from red ginseng-fed rats.Journal of Ginseng Research. 2013;37:371-378.
  • Karabina SA, Elisaf M, Bairaktari E, Tzallas C, Siamopoulos KC, Tselepis AD.Increased activity of platelet-activating factor acetylhydrolase in low-densitylipoprotein subfractions induces enhanced lysophosphatidylcholine production duringoxidation in patients with heterozygous familial hypercholesterolaemia. Eur J ClinInvest. 1997;27:595-602.
  • Jung, N.P., Jin, S.H., Studies on the physiological and biochemical effects of Koreanginseng. Korean J. Ginseng Sci. 1996. 20;4:431-471.35
  • Jovanovski, E., Peeva, V., Sievenpiper, J. L., Jenkins, A. L., Desouza, L., Rahelic, D.,Vuksan, V. Modulation of endothelial function by Korean red ginseng (Panax ginsengC.A. Meyer) and its components in healthy individuals: a randomized controlled trial.Cardiovascular Therapeutics. 2014;32:163-169.
  • Jovanovski, E., Jenkins, A., Dias, A. G., Peeva, V., Sievenpiper, J., Arnason, J. T.,Vuksan V. Effects of Korean red ginseng (Panax ginseng C.A. Mayer) and its isolatedginsenosides and polysaccharides on arterial stiffness in healthy individuals. AmericanJournal of Hypertension. 2010;23:469-472.34
  • Jovanovski, E., Bateman, E. A., Bhardwaj, J., Fairgrieve, C., Mucalo, I., Jenkins, A. L.,& Vuksan V. Effect of Rg3-enriched Korean red ginseng (Panax ginseng) on arterialstiffness and blood pressure in healthy individuals: a randomized controlled trial.Journal of the American Society of Hypertension. 2014;8:537-541.
  • Joint National Committee on Prevention, Detection, Evaluation, and Treatment of HighBlood Pressure. The sixth report of the Joint National Committee on Prevention,Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med.1997;157:2413?2446.
  • Jiang, H., Nie, L., Li, Y., & Xie, J. (2012). Application of ultra-performance liquidchromatography coupled with mass spectrometry to metabonomic study onspontaneously hypertensive rats and intervention effects of Ping Gan prescription.Journal of Separation Science. 2012;35:483-489.
  • Jellin, J. M., Batz, F., & Hitchens, K. (Eds.). Pharmacist s letter/prescriber s letternatural medicines comprehensive database. Stockton, CA: Therapeutic ResearchFaculty. 1999.40
  • Inoue N, Takeshita S, Gao D, Ishida T, Kawashima S, Akita H, Tawa R, Sakurai H,Yokoyama M. Lysophosphatidylcholine increases the secretion of matrixmetalloproteinase 2 through the activation of NADH/NADPH oxidase in culturedaortic endothelial cells. Atherosclerosis. 2001;155:45-52.
  • Hakkinen T, Luoma JS, Hiltunen MO, Macphee CH, Milliner KJ, Patel L, Rice SQ,Tew DG, Karkola K, Yla-Herttuala S. Lipoprotein-associated phospholipase A(2),platelet-activating factor acetylhydrolase, is expressed by macrophages in human andrabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol.1999;19:2909-2917.39
  • Glasser, S. P., Khodneva, Y., Lackland, D. T., Prineas, R., & Safford, M. M.Prehypertension and incident acute coronary heart disease in the Reasons for Geographicand Racial Differences in Stroke (REGARDS) study. American Journal of Hypertension.2014;27:245-251.
  • Giuseppe, A., Andreas, E., Nuno, V.D., Jan, N., Prehn, C., Adamski, J., & Goncalves,I. Treatment with beta-blockers is associated with lower levels of Lp-PLA2 and suPARin carotid plaques. Cardiovascular. Pathology. 2013;22:438-443.41
  • Fitzloff, J. F., Yat, P., Lu, Z. Z., Awang, D. V. C., Amason, J. T., Van Breemen, R. B.,Fong, H. H. S. Perspectives on the Quality Assurance of Ginseng Products in NorthAmerica. In H. Huh (Chair), The Korean Society of Ginseng. Proceedings in the 7thInternational Symposium on Ginseng, Seoul, Korea(1998, September).
  • Dong-Hyun Kim, Chemical Diversity of Panax ginseng, Panax quinquifolium, andPanax notoginseng, J. Ginseng Res. 2012;36:1-15.
  • Danaei, G., Finucane, M. M., Lin, J. K., Singh G. M., Paciorek, C. J., Cowan, M. J.,Ezzati, M. National, regional, and global trends in systolic blood pressure since 1980:systematic analysis of health examination surveys and epidemiological studies with 786country-years and 5 4 million participants. Lancet. 2011;377:568-577.
  • Christian, J. L., & Greger, J. L. (Ed.). Energy sources and uses - Nutrition for Living.Redwood City, CA: Benjamin/Cummings Publishing Co. 2014;4:242-266.
  • Choi, K.T. Botanical characteristics, pharmacological effects and medicinalcomponents of Korean Panax ginseng C A Meyer. Acta Pharmacol Sin. 2008;29:1109-1118.
  • Choi, J. H., Kim, W. J., Yang, J. W., Sung, H. S., Hong, S.K. Quality changes in RedGinseng Extract During High Temperature Storage. J. Korean Agric. Chem. SOC.1981;24(1):50.
  • Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L.Jr., Roccella, E. J. The seventh report of the Joint National Committee on prevention,detection, evaluation, and treatment of high blood pressure: the JNC 7 report, JAMA.2003;289:2560-2572.
  • Chaudhuri P, Colles SM, Damron DS, Graham LM. Lysophosphatidylcholine inhibitsendothelial cell migration by increasing intracellular calcium and activating calpain.Arterioscler Thromb Vasc Biol. 2003;23:218-223.
  • Charo IF, Taub R. Anti-inflammatory therapeutics for the treatment of atherosclerosis.Nat Rev Drug Discov. 2011;10:365-376.
  • Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH.Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase:a potential new risk factor for coronary artery disease. Atherosclerosis. 2000;150:413-419.
  • Caron, M. F., Hotsko, A. L., Robertson, S., Mandybur, L., Kluger, J., & White, C. M.Electrocardiographic and hemodynamic effects of Panax ginseng. The Annals ofPharmacotherapy. 2002;36:758-763.
  • Buettner, C., Yeh, G. Y., Phillips, R. S., Mittleman, M. A., & Kaptchuk, T. J.Systematic review of the effects of ginseng on cardiovascular risk factors. The Annalsof Pharmacotherapy. 2006;40:83-95.
  • Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents andmultiple actions. Biochem Pharmacol, 1999;58:1685-1693.